Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

On the basis of these findings and clinical experience, individuals with Becker muscular dystrophy (BMD) are advised to avoid excess physical exertion. Sveen et al. have performed the first study ...

Edgewise Therapeutics' stock soars on positive Becker Muscular Dystrophy trial results. Learn why EWTX is a promising buy with derisked programs.

Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...

The skeletal phenotype in Becker muscular dystrophy: The under-studied cousin of Duchenne Title: P19: Myosin inhibitor EDG-4131 improves pathophysiology and molecular pathology in BMD model mice ...

including Becker Muscular Dystrophy (BMD) and Duchenne Muscular Dystrophy (DMD). EDG-7500 is Edgewise's most advanced program, currently in Phase 2 clinical trials for the treatment of HCM.

Lastly, Edgewise Therapeutics reported favorable Phase 2 data from its Becker Muscular Dystrophy (BMD) trial, a development that led Truist Securities to reiterate its Buy rating and steady price ...

Title: P10: Prediction of North Star Ambulatory Assessment trajectories in Becker muscular dystrophy: Model development and validation Title: P11: Two-year sevasemten treatment outcomes in Becker ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...